Jennifer C. Lai, Amy M. Shui, Andres Duarte‐Rojo, Daniel R. Ganger, Robert S. Rahimi, Chiung‐Yu Huang, Frederick Yao, Matthew Kappus, Brian Boyarsky, Mara McAdams‐Demarco, Michael L. Volk, Michael A. Dunn, Daniela P. Ladner, Dorry L. Segev, Elizabeth C. Verna, Sandy Feng, from the Multi‐Center Functional Assessment in Liver Transplantation (FrAILT) Study – 3 December 2021

Zhujun Cao, Honglian Gui, Zike Sheng, Haiguang Xin, Qing Xie – 3 December 2021

M. Andrew Millis, Shannon L. Cramm, Michael Englesbe – 2 December 2021

Andrew I. Aronsohn, Debika Bhattacharya, Timothy R. Morgan, David L. Wyles, Raymond T. Chung, Daniel P. McQuillen, AASLD‐IDSA HCV Guidance – 2 December 2021

Alyson Kaplan, Russell Rosenblatt, Whitney Jackson, Benjamin Samstein, Robert S. Brown – 2 December 2021 – Living donor liver transplantation (LDLT) remains underutilized in the United States. Barriers to LDLT and acceptance of nondirected living liver donation (ND‐LLD) and liver paired exchange (LPE) are unclear. The medical and surgical directors of 99 unique transplantation programs (56 LDLT programs and 43 non‐LDLT programs) were surveyed to gain insight into perceptions and practices of LDLT and types of donors utilized. The response rate was 84%.

Karim T. Osman, Tarek Nayfeh, Ahmed M. Abdelfattah, Khaled Alabdallah, Bashar Hasan, Mohammed Firwana, Homam Alabaji, Lina Elkhabiry, Jehan Mousa, Larry J. Prokop, M. Hassan Murad, Fredric Gordon – 2 December 2021 – There is no clear consensus regarding the optimal approach for secondary prophylaxis of gastric variceal bleeding (GVB) in patients with cirrhosis. We conducted a systematic review and network meta‐analysis (NMA) to compare the efficacy of available treatments.

Adi Balk, Jarone Lee, Christian Renne, Shuhan He – 2 December 2021

Alyson N. Fox, AnnMarie Liapakis, Ramesh Batra, Therese Bittermann, Juliet Emamaullee, Sukru Emre, Yuri Genyk, Hyosun Han, Whitney Jackson, Elizabeth Pomfret, Muhammad Raza, Manuel Rodriguez‐Davalos, Susan Rubman Gold, Benjamin Samstein, Akhil Shenoy, Timucin Taner, John P.

Cihan Yurdaydin, Onur Keskin, Esra Yurdcu, Aysun Çalişkan, Soner Önem, Fatih Karakaya, Çağdaş Kalkan, Ersin Karatayli, Senem Karatayli, Ingrid Choong, David Apelian, Christopher Koh, Theo Heller, Ramazan Idilman, A. Mithat Bozdayi, Jeffrey S. Glenn – 2 December 2021

Gonzalo Sapisochin, Tommy Ivanics, Julie Heimbach – 2 December 2021 – Cholangiocarcinoma (CCA) represents the second‐most common primary liver malignancy after HCC and has risen in incidence globally in the past decades. Intrahepatic cholangiocarcinoma (iCCA) comprises 20% of all CCAs, with the rest being extrahepatic (including perihilar [pCCA] and distal CCA). Though long representing an absolute contraindication for liver transplantation (LT), recent analyses of outcomes of LT for iCCA have suggested that iCCA may be a potentially feasible option for highly selected patients.